These scientific publications and presentations are provided for educational purposes only. They may discuss or mention DBV Technologies’ products under clinical investigation, which have not been approved for marketing by any health or regulatory authority in any country.

• Remington BC, Campbell DE, et al. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. doi: 10.1016/j.anai.2020.11.015.
• Brown-Whitehorn TF, de Blay F, et al. Sustained Unresponsiveness to Peanut After Long-term Peanut Epicutaneous Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. doi: 10.1016/j.jaip.2020.08.017.
• DunnGalvin A, Fleischer DM, et al. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. doi: 10.1016/j.jaip.2020.08.015.
• Fleischer DM, Shreffler WG, et al. Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy For Peanut Allergy in Children: PEOPLE 3-Year Results. The Journal of Allergy and Clinical Immunology. 2020. doi:10.1016/j.jaci.2020.06.028.
• Fleischer DM, Chinthrajah S, et al. An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy For Peanut Allergy in the PEPITES Trial. Allergy & Asthma Proceedings. 2020;41:1-10. doi:10.2500/aap.2020.41.200047. PMID: 32539908.
• Fleischer DM, Spergel JM, et al. Evaluation of Daily Patch Application Duration For Epicutaneous Immunotherapy For Peanut Allergy. Allergy & Asthma Proceedings. 2020;41:278-284. doi:10.2500/aap.2020.41.200045. PMID: 32517847.
• Greenhawt M, Kim EH, et al. Improvements in Eliciting Dose Across Baseline Sensitivities Following 12 Months of Epicutaneous Immunotherapy (EPIT) in Peanut-Allergic Children Aged 4 to 11 Years. The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. doi:10.1016/j.jaip.2020.05.030. PMID: 32502548.
• Remington BC, Krone T, et al. Estimated Risk Reduction to Packaged Food Reactions by Epicutaneous Immunotherapy (EPIT) For Peanut Allergy. Annals of Allergy, Asthma & Immunology. 2019;123(5):488‐493.e2. doi:10.1016/j.anai.2019.08.007. PMID: 31442495.
• Fleischer DM, Greenhawt M, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. doi:10.1001/jama.2019.1113. PMID: 30794314.
• Sampson HA, Shreffler WG, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. doi:10.1001/jama.2017.16591. PMID: 29136445.

While these abstracts were accepted for presentation at medical congresses, these have not been subjected to full peer review and present only initial, preliminary findings, which may differ from those that could appear in later, complete manuscripts and peer-reviewed publications.

Oral Presentations:

• Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy (Abstract 7202)

Poster Presentations:

• An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy for Peanut Allergy in the PEPITES Trial (Abstract P301)
• Evaluation of Daily Patch Application Duration for Epicutaneous Immunotherapy for Peanut Allergy (Abstract P300)
• Patient Experiences with Epicutaneous Immunotherapy for Peanut Allergy in OLFUS-VIPES & REALISE Trials: Qualitative Studies (Abstract P307)

Oral Presentations:

• Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects With and Without Concomitant Food Allergies (Abstract 1362)
• Late Breaker: Differences in Epitome Response in Peanut-Allergic Subjects Treated with Different Immunotherapy Preparations (Abstract 1776)
• Late Breaker: Epicutaneous Immunotherapy in Murine Model Modulates Humoral Immunity Through Regulation of IL-13+ T Follicular Helper Cells (Abstract 1739)
• Late Breaker: Distinct Contribution of Skin Dendritic Cell Subsets to the Efficacy of Epicutaneous Immunotherapy in Murine Models of Food Allergy (Abstract 1747)

Poster Presentations:

• Evaluation of Psychometric Parameters of Food Allergy Quality-of-Life Questionnaires With Item Response Theory for the Assessment of Health-Related Quality of Life during Food Allergy Treatments (Abstract 1247)
• Late Breaker: Quality of Life of Children and Adolescents With Food Allergy: Mapping FAQLQ-PF onto Paediatric-Specific Health State Utility Scores (Abstract 1719)
• Safety Benefits of an Increased Threshold in Milk-Allergic Patients: A Quantitative Risk Assessment Study (Abstract 1192)

Oral Presentations:

• Results of the REALISE (Real-life Use and Safety of EPIT) Study: A Multicenter Blinded Randomized Controlled Trial Investigating the Safety of Epicutaneous Immunotherapy for Peanut Allergy in Peanut-Allergic Children (Abstract 257)
• Role of Langerhans Cells in the Formation of Germinal Center and Modulation of Humoral Immunity During Epicutaneous Immunotherapy (Abstract 266)
• Mechanisms of Allergen Capture by Skin DC Differ Between Naïve and Sensitized Individuals in a Specific-IgG Dependent Manner (Abstract 527)

Poster Presentations:

• Open-Label Follow-Up of the PEPITES Study (PEOPLE) to Evaluate the Long-Term Efficacy and Safety of Epicutaneous Peanut Immunotherapy in Peanut-Allergic Children (Abstract 449)
• Modeled Quantitative Risk Reduction Through Epicutaneous Immunotherapy for Peanut Allergy: Restaurant Meal Preparation with Shared Cooking Utensils and Equipment (Abstract 451)
• Food Allergy Quality of Life Questionnaires for Assessment of Health-Related Quality of Life in Clinical Food Allergy Treatment Studies: Use of Item Response Theory (Abstract 444)